Treatment Of Schizophrenia With Cobenfy (KarXT): A Literature Review

Treatment Of Schizophrenia With Cobenfy (KarXT): A Literature Review

Introduction and purpose: In September 2024, the FDA approved a new drug for the treatment of schizophrenia in adults, Cobenfy, also known as KarXT. COBENFY combines xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist. It is the first antipsychotic approved for the trea...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Kurczoba, Karolina Skonieczna, Magdalena Badziąg, Paulina Szulc, Martyna Kłossowska, Olimpia Wiciun, Olga Kądziołka, Kacper Ordon
Format: Article
Language:English
Published: Nicolaus Copernicus University in Toruń 2025-05-01
Series:Quality in Sport
Subjects:
schizophrenia
dopamine hypothesis
cholinergic hypothesis
xanomeline
trospium
Online Access:https://apcz.umk.pl/QS/article/view/60359
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://apcz.umk.pl/QS/article/view/60359

Similar Items